Miami, FL – March 7, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on AngioSoma, Inc. (OTC Pink: SOAN).

AngioSoma, Inc. operates as a clinical stage biotechnology company. The company’s lead drug candidates include Liprostin that completed Phase I and three Phase II clinical trials, and Prostaglandin E1 that completed Phase II clinical trials for the treatment of peripheral artery diseases. It also markets a line of nutraceutical supplements under the SomaCeuticals name. 

Average daily volume for SOAN is 1.5 million shares. Today’s news has caused the volume to increase to over 1.9 million shares in the morning hours of trading.

AngioSoma, Inc.Press Release:

Houston, TX, March 06, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma, Inc. (SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief LLC, whose patented process and procedures treat the root cause of diabetes, instead of just the symptoms, resulting in patient improvement greater than with conventional treatment. 

Diabetes Relief Adds Key Milestones for 2019

Diabetes Relief is meeting its goals for new licensed facilities by adding a third Houston captive facility and licensing new centers in Austin, California, and Florida. “Diabetes Relief is poised to improve the lives of millions of diabetics all over the world,” said Scott Hepford, Manager of Diabetes Relief LLC.  

Diabetes Relief’s Georgia Facility Exceeds Expectations

Diabetes Relief reports that its licensee in Southeast Georgia has exceeded all hopes for profitability and patient improvements and is looking to expand to Atlanta. “This is what we have envisioned for the Company, and it is exciting to see it happen,” stated Brian Loveridge, MD, Regional Medical Director for Diabetes Relief LLC. “As Diabetes Relief continues to see improvement where conventional treatment has failed, the demand for its patented product are booming,” Dr. Loveridge added. Kerrie Dawson, CEO of DR’s first Georgia expansion, reported that “DR is worth the investment in so many ways for a practice, and we have saved one lady’s leg from amputation!” 

Diabetes Relief Licensed Facilities Grow to 11

With the addition of licensed facilities in Jacksonville, Florida, and Thousand Oaks, California, Diabetes Relief’s patented treatment is now offered in 11 facilities and the company is working hard to keep up with the demand for licenses. “We are making plans for a comprehensive peer-reviewed, double-blind study of our amazing process that is changing so many lives once believed hopeless,” said Dr. Stanley Lewis, the Company’s Chief Medical Officer, “while handling the many requests for licenses.”   

ABOUT DIABETES RELIEF LLC 

Diabetes Relief LLC is a privately-held company that began in 2015 with one facility in Houston. Diabetes Relief’s patented process helps patients with all metabolic disorders, dominated by diabetes. Patients report improvements with Diabetes Relief’s physiologic insulin administration that they have found nowhere else and with no other treatment or prescription drugs. Its rapidly growing licensees now provide services and products in 5 states and 3 other countries that promote healthier living and an improved quality of life for those living with diabetes and other metabolic dysfunction. Information and patient testimonials are available at www.diabetesrelief.com.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (https:// angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.CONTACT

AngioSoma, Inc.
Alex Blankenship
investors@AngioSoma.com
(832) 781-8521


About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  EmergingGrowth.com, or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, http://emerginggrowth.com/disclosure/. Please consult an investment professional before investing in anything viewed within this article or any other portion of EmergingGrowth.com. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments